I've published
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
Clin. Cancer Res., Mar;14(5):1446-54 (2008)
Dr. Eyal Attar, Dr. Karen Ballen, Dr. Elizabeth Trehu
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.
Clin. Cancer Res., May;17(9):2977-86 (2011)
Dr. Eyal Attar, Dr. Karen Ballen, Dr. Philippe Armand, Dr. Ephraim Hochberg, Dr. Jennifer Brown, Dr. Robert Hasserjian
The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.
Leuk. Lymphoma., May;52(5):754-63 (2011)
Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study.
Am. J. Hematol., Oct;35(2):80-3 (1990)
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck.
Ann. Oncol., May;11(5):535-9 (2000)
Dr. Alexander Colevas, Dr. Marshall Posner
Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study.
Oral Oncol., Oct;39(7):724-7 (2003)
Dr. Alexander Colevas
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Clin. Cancer Res., Apr;10(7):2222-30 (2004)
Dr. Joseph Eder
Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.
Cancer., Oct;104(7):1418-27 (2005)
Dr. Daniel Deschler
ELF4 is fused to ERG in a case of acute myeloid leukemia with a t(X;21)(q25-26;q22).
Leuk. Res., Aug;30(8):1037-42 (2006)
Dr. Judith Ferry
Diffuse cellular and fibrosing interstitial pneumonitis with desquamative interstitial pneumonitis-like features associated with myeloid neoplasia.
Am. J. Surg. Pathol., Oct;33(10):1485-93 (2009)
Dr. Reginald Greene, Dr. Eugene Mark, Dr. Richard Kradin, Dr. Robert Hasserjian
Genomic alterations in myeloid neoplasms with novel, apparently balanced translocations.
Cancer Genet., Feb;204(2):68-76 (2011)
Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations.
Leuk. Res., Dec;35(12):1611-5 (2011)
Dr. Eyal Attar, Dr. Karen Ballen
Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.
Blood., Feb;89(3):780-8 (1997)
An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B.
Leukemia., Feb;12(2):139-43 (1998)
Dr. Paolo Paciucci
A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck.
Cancer., Jul;92(2):326-31 (2001)
Dr. Alexander Colevas, Dr. Marshall Posner
Hematologic changes in anorexia nervosa.
JAMA., May;241(20):2190-1 (1979)
Phase II trial of m-AMSA therapy in refractory Hodgkin's disease and non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 7972.
Cancer Treat Rep., Oct;70(10):1233-4 (1986)
Dr. George Canellos
Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous carcinoma.
Cancer., Apr;71(7):2326-31 (1993)
Dr. Susan Urba